Cargando…

A pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer

BACKGROUND: Cell division cycle 6 (cdc6) is a key factor of DNA replication initiation license system and a proto‐oncogene. It has been detected in some tumor tissues to aid cancer diagnosis in many research projects. However, it remains unclear that if cdc6 could be detected in the peripheral blood...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Cheng, Liu, Guijian, Cheng, Shi, Pang, Bo, Sun, Shipeng, Zhang, Yaying, Pan, Zhongdai, Kang, Xixiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307357/
https://www.ncbi.nlm.nih.gov/pubmed/32249466
http://dx.doi.org/10.1002/jcla.23245
_version_ 1783548793428377600
author An, Cheng
Liu, Guijian
Cheng, Shi
Pang, Bo
Sun, Shipeng
Zhang, Yaying
Pan, Zhongdai
Kang, Xixiong
author_facet An, Cheng
Liu, Guijian
Cheng, Shi
Pang, Bo
Sun, Shipeng
Zhang, Yaying
Pan, Zhongdai
Kang, Xixiong
author_sort An, Cheng
collection PubMed
description BACKGROUND: Cell division cycle 6 (cdc6) is a key factor of DNA replication initiation license system and a proto‐oncogene. It has been detected in some tumor tissues to aid cancer diagnosis in many research projects. However, it remains unclear that if cdc6 could be detected in the peripheral blood, just like liquid biopsy, in solid tumor patients. The aim of this study is to investigate the possibility of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer. METHODS: We first detected the expression of cdc6 in peripheral blood mononuclear cells (PBMCs) and tumor cells by in situ hybridization with cdc6 RNA probe. Then, we examined the expression of cdc6 in PBMCs from health individual, mononuclear cells from cord blood, or A549 cell line by RT‐qPCR. Furthermore, we used RT‐qPCR to test the cdc6 expression in PBMCs from tumor patients (test group) and non‐tumor individuals as a control group. Chi‐square test with Fisher's exact test was used to analyze the statistical significance of the difference. P < .05 is considered as statistically significant difference. RESULTS: When compared the cdc6 expression in cells from difference sources, we found that A549 tumor cell line had the strongest expression of cdc6, samples from cord blood showed the least expression level, indicating the detection strategy of RT‐qPCR is reasonable. Using this method, we studied whether cdc6 in Peripheral blood could be detected as a biomarker by examining cdc6 expression from PBMCs of patients with lung cancer. We found 20% of patients with lung cancer were cdc6 positive in PBMCs, whereas only 4.26% was found positive in the control group (P = .039, P < .05). CONCLUSION: Cell division cycle 6 has a potential to be used as a circulating tumor cell biomarker for lung cancer. Further study in clinical application is still broad needed.
format Online
Article
Text
id pubmed-7307357
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-73073572020-06-23 A pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer An, Cheng Liu, Guijian Cheng, Shi Pang, Bo Sun, Shipeng Zhang, Yaying Pan, Zhongdai Kang, Xixiong J Clin Lab Anal Research Articles BACKGROUND: Cell division cycle 6 (cdc6) is a key factor of DNA replication initiation license system and a proto‐oncogene. It has been detected in some tumor tissues to aid cancer diagnosis in many research projects. However, it remains unclear that if cdc6 could be detected in the peripheral blood, just like liquid biopsy, in solid tumor patients. The aim of this study is to investigate the possibility of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer. METHODS: We first detected the expression of cdc6 in peripheral blood mononuclear cells (PBMCs) and tumor cells by in situ hybridization with cdc6 RNA probe. Then, we examined the expression of cdc6 in PBMCs from health individual, mononuclear cells from cord blood, or A549 cell line by RT‐qPCR. Furthermore, we used RT‐qPCR to test the cdc6 expression in PBMCs from tumor patients (test group) and non‐tumor individuals as a control group. Chi‐square test with Fisher's exact test was used to analyze the statistical significance of the difference. P < .05 is considered as statistically significant difference. RESULTS: When compared the cdc6 expression in cells from difference sources, we found that A549 tumor cell line had the strongest expression of cdc6, samples from cord blood showed the least expression level, indicating the detection strategy of RT‐qPCR is reasonable. Using this method, we studied whether cdc6 in Peripheral blood could be detected as a biomarker by examining cdc6 expression from PBMCs of patients with lung cancer. We found 20% of patients with lung cancer were cdc6 positive in PBMCs, whereas only 4.26% was found positive in the control group (P = .039, P < .05). CONCLUSION: Cell division cycle 6 has a potential to be used as a circulating tumor cell biomarker for lung cancer. Further study in clinical application is still broad needed. John Wiley and Sons Inc. 2020-04-06 /pmc/articles/PMC7307357/ /pubmed/32249466 http://dx.doi.org/10.1002/jcla.23245 Text en © 2020 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
An, Cheng
Liu, Guijian
Cheng, Shi
Pang, Bo
Sun, Shipeng
Zhang, Yaying
Pan, Zhongdai
Kang, Xixiong
A pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer
title A pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer
title_full A pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer
title_fullStr A pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer
title_full_unstemmed A pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer
title_short A pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer
title_sort pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307357/
https://www.ncbi.nlm.nih.gov/pubmed/32249466
http://dx.doi.org/10.1002/jcla.23245
work_keys_str_mv AT ancheng apilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer
AT liuguijian apilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer
AT chengshi apilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer
AT pangbo apilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer
AT sunshipeng apilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer
AT zhangyaying apilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer
AT panzhongdai apilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer
AT kangxixiong apilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer
AT ancheng pilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer
AT liuguijian pilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer
AT chengshi pilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer
AT pangbo pilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer
AT sunshipeng pilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer
AT zhangyaying pilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer
AT panzhongdai pilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer
AT kangxixiong pilotstudyofcdc6asabiomarkerforcirculatingtumorcellsinpatientswithlungcancer